We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+15.71%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.12B
AUM Growth
+$363M
Cap. Flow
+$161M
Cap. Flow %
7.62%
Top 10 Hldgs %
72.29%
Holding
40
New
2
Increased
23
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$40.4M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$37.6M
3
EPZM
Epizyme, Inc
EPZM
+$23.4M
4
ALGN icon
Align Technology
ALGN
+$18.6M
5
AIMT
Aimmune Therapeutics
AIMT
+$16.3M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$33.4M
2
PGEN icon
Precigen
PGEN
+$8.42K

Sector Composition

Rank Sector Weight
1 Healthcare 95.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$23.1B
$255M 12.05%
1,883,315
+14,500
+0.8% +$2.2M
CLVS
2
DELISTED
Clovis Oncology, Inc.
CLVS
$248M 11.72%
3,894,963
+90,875
+2% +$5.52M
ABMD
3
DELISTED
Abiomed Inc
ABMD
$241M 11.37%
1,921,484
+17,900
+0.9% +$2.07M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$12.4B
$209M 9.89%
2,382,619
+422,400
+22% +$37.6M
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$125M 5.89%
1,027,060
+313,318
+44% +$40.4M
ZLTQ
6
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$113M 5.34%
2,032,692
+311,929
+18% +$15.6M
INSM icon
7
Insmed
INSM
$28.6B
$96.9M 4.58%
5,534,150
+87,634
+2% +$1.35M
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$82.2M 3.88%
4,791,051
+1,755,255
+58% +$23.4M
WMGI
9
DELISTED
Wright Medical Group Inc
WMGI
$81.8M 3.87%
2,628,193
+23,600
+0.9% +$640K
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$78.3M 3.7%
1,101,951
+92,021
+9% +$5.39M
AMAG
11
DELISTED
AMAG Pharmaceuticals
AMAG
$75.4M 3.56%
3,344,620
– –
PRTA icon
12
Prothena Corp
PRTA
$450M
$58.9M 2.78%
1,055,855
+62,000
+6% +$3.26M
VNDA icon
13
Vanda Pharmaceuticals
VNDA
$302M
$58.8M 2.78%
4,203,270
– –
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$56.2M 2.66%
7,882,988
+1,472,958
+23% +$9.31M
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$5.03B
$54.7M 2.58%
1,590,430
+58,400
+4% +$2.06M
KPTI icon
16
Karyopharm Therapeutics
KPTI
$48M
$43.7M 2.07%
227,098
+13,738
+6% +$2.21M
CELG
17
DELISTED
Celgene Corp
CELG
$36.7M 1.74%
295,240
– –
STAA icon
18
STAAR Surgical
STAA
$1.21B
$34M 1.61%
3,473,170
+86,925
+3% +$867K
ALGN icon
19
Align Technology
ALGN
$12.3B
$25.6M 1.21%
223,107
+184,400
+476% +$18.6M
AIMT
20
DELISTED
Aimmune Therapeutics
AIMT
$25.5M 1.21%
1,173,498
+793,771
+209% +$16.3M
GILD icon
21
Gilead Sciences
GILD
$165B
$23.9M 1.13%
351,600
+33,200
+10% +$2.33M
MNTA
22
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$23.5M 1.11%
1,759,376
+31,996
+2% +$501K
SHPG
23
DELISTED
Shire pic
SHPG
$22.7M 1.07%
130,200
+6,100
+5% +$1.07M
RIGL icon
24
Rigel Pharmaceuticals
RIGL
$750M
$14.1M 0.67%
425,462
+7,800
+2% +$199K
EXAS
25
DELISTED
Exact Sciences
EXAS
$10M 0.47%
425,276
+28,300
+7% +$561K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q1 2017 Portfolio in Review

As of Q1 2017, Palo Alto Investors held 40 positions worth $2.12B, up 21% from $1.75B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Palo Alto Investors deployed $161M of net new capital in Q1 2017, opening 2 new positions and adding to 23 existing holdings. Its largest new stake was Trevena, Inc.: 546 shares worth $1.25M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Precigen, an estimated $8.42K trimmed.

  • Palo Alto Investors's largest Q1 2017 buy was Trevena, Inc.: 546 shares worth $1.25M.
  • Palo Alto Investors added most to Alexion Pharmaceuticals in Q1 2017, an estimated $40.4M increase.
  • Palo Alto Investors's biggest Q1 2017 reduction was Precigen, cutting an estimated $8.42K.
  • Palo Alto Investors fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $33.4M.
  • Palo Alto Investors's ten largest holdings make up 72% of its $2.12B portfolio in Q1 2017.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q1 2017.
  • Palo Alto Investors's portfolio value rose 21% quarter-over-quarter to $2.12B.

Based on Palo Alto Investors's 13F filing for Q1 2017, filed 15 May 2017.